Nephrology

Phase 2 JASMINE data show nipocalimab achieved SRI-4 response rates of 53.5% vs 46.7% with placebo at week 24, with benefits sustained through week 52.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

An expert describes his perspective on sequencing, APRIL inhibition, proteinuria endpoints, and long-term kidney preservation in IgA nephropathy.

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

Susztak, MD, PhD, offers insight into a new score that predicts which APOL1 carriers will actually develop kidney disease.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data.

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

Garimella, MBBS, unpacks what clinicians need to know about APOL1-mediated kidney disease, including misclassification, testing barriers, and management gaps.

Campbell answers questions about the current research and clinical landscape of APOL1-mediated kidney disease.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA.

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

Catch up on nephrology headlines you missed from Q1 2026.

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN.

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan.

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.